Literature DB >> 18206980

Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450.

Maude Fer1, Yvonne Dréano, Danièle Lucas, Laurent Corcos, Jean-Pierre Salaün, François Berthou, Yolande Amet.   

Abstract

Epoxidation and hydroxylation of arachidonic acid (AA) are both catalyzed by cytochromes P450s (CYPs). The oxidized metabolites are known to be involved in the regulation of vascular tone and renal function. By using a panel of 15 human recombinant CYPs, this study demonstrates that other polyunsaturated long-chain fatty acids (PUFA-LC), especially the omega3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are also epoxidised. The regioselectivity of epoxidation of four PUFA-LC by CYPs was investigated. Among the several CYPs tested, CYP2C9/2C19 and 1A2 were the most efficient in EPA and DHA epoxidations. It ensued that 10muM of these two omega3 fatty acids decreased by more than 80% and 60%, respectively, the formation by CYP2C9 of AA-epoxidised derivatives. These findings suggest that some physiological effects of omega3 fatty acids may be due to a shift in the generation of active epoxidised metabolites of AA through CYP-mediated catalysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18206980     DOI: 10.1016/j.abb.2008.01.002

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  54 in total

1.  Activation of vascular BK channels by docosahexaenoic acid is dependent on cytochrome P450 epoxygenase activity.

Authors:  Ru-xing Wang; Qiang Chai; Tong Lu; Hon-Chi Lee
Journal:  Cardiovasc Res       Date:  2010-12-27       Impact factor: 10.787

Review 2.  The role of AHR-inducible cytochrome P450s in metabolism of polyunsaturated fatty acids.

Authors:  Oliver Hankinson
Journal:  Drug Metab Rev       Date:  2016-06-30       Impact factor: 4.518

Review 3.  Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Authors:  W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha
Journal:  Neurosci Biobehav Rev       Date:  2018-02-02       Impact factor: 8.989

Review 4.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

5.  Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway.

Authors:  Robert Fischer; Anne Konkel; Heidrun Mehling; Katrin Blossey; Andrej Gapelyuk; Niels Wessel; Clemens von Schacky; Ralf Dechend; Dominik N Muller; Michael Rothe; Friedrich C Luft; Karsten Weylandt; Wolf-Hagen Schunck
Journal:  J Lipid Res       Date:  2014-03-16       Impact factor: 5.922

6.  Dietary Omega-3 Polyunsaturated Fatty Acids Prevent Vascular Dysfunction and Attenuate Cytochrome P4501A1 Expression by 2,3,7,8-Tetrachlorodibenzo-P-Dioxin.

Authors:  Elani F Wiest; Mary T Walsh-Wilcox; Michael Rothe; Wolf-Hagen Schunck; Mary K Walker
Journal:  Toxicol Sci       Date:  2016-08-04       Impact factor: 4.849

Review 7.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

8.  Treatment of mice with 2,3,7,8-Tetrachlorodibenzo-p-dioxin markedly increases the levels of a number of cytochrome P450 metabolites of omega-3 polyunsaturated fatty acids in the liver and lung.

Authors:  Jun Yang; Parrisa Solaimani; Hua Dong; Bruce Hammock; Oliver Hankinson
Journal:  J Toxicol Sci       Date:  2013       Impact factor: 2.196

9.  Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450.

Authors:  Danièle Lucas; Sophie Goulitquer; Jan Marienhagen; Maude Fer; Yvonne Dreano; Ulrich Schwaneberg; Yolande Amet; Laurent Corcos
Journal:  J Lipid Res       Date:  2009-11-25       Impact factor: 5.922

10.  Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer.

Authors:  M Robyn Andersen; Erin Sweet; Kimberly A Lowe; Leanna J Standish; Charles W Drescher; Barbara A Goff
Journal:  J Altern Complement Med       Date:  2013-02-27       Impact factor: 2.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.